This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Hagens Berman Adds Five Cases To Thalidomide Litigation

Hagens Berman Sobol Shapiro LLP (HBSS) has filed a new case on behalf of five alleged victims of multiple German and North American companies, charging that they or their predecessors concealed the distribution of the drug thalidomide to pregnant women in the 1960s, allegedly causing birth defects across the United States.

The suit, filed on Aug. 7, 2013, brings the number of clients Hagens Berman represents to 49. The firm first brought attention to this matter when it filed its first lawsuit in 2011.

The most recent filing in state court in Pennsylvania names Avantor Performance Materials, GlaxoSmithKline (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), and Grünenthal GmbH as defendants, as well as some of their subsidiaries.

According to court documents, recent research suggests that thalidomide—a drug that caused thousands of horrific cases of deformities in children—caused far more deformities in the U.S. than originally thought.

Invented by German drug company Grunenthal, thalidomide was widely used throughout Europe during the late 1950s and early 1960s, resulting in thousands of deaths and extreme, disfiguring birth defects when used by women during pregnancy.

The drug was never approved for commercial distribution in the United States, but the new lawsuit filed today by HBSS on behalf of five individuals—all born with severe birth defects—alleges that as many as 2.5 million doses of thalidomide were distributed by more than 1,200 doctors to more than 20,000 people on U.S. soil, including pregnant women. The lawsuit is the latest in a series of suits filed by individuals who claim that their mothers were given thalidomide while they were in the womb, and who suffered serious injuries or birth defects as a result.

The lawsuit claims that Richardson-Merrell, a pharmaceutical company now owned by Sanofi-Aventis (NYSE: SNY) conducted large-scale “clinical trials” with thalidomide that involved more than 20,000 people, including pregnant women, in the early 1960s.

Stock quotes in this article: GSK, SNY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs